These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 23199039)
21. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Seljeflot I; Tonstad S; Hjermann I; Arnesen H Atherosclerosis; 2002 May; 162(1):179-85. PubMed ID: 11947912 [TBL] [Abstract][Full Text] [Related]
22. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Freestone B; Chong AY; Nuttall S; Blann AD; Lip GY Chest; 2007 Oct; 132(4):1253-8. PubMed ID: 17890461 [TBL] [Abstract][Full Text] [Related]
23. Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes. Beer S; Feihl F; Ruiz J; Juhan-Vague I; Aillaud MF; Wetzel SG; Liaudet L; Gaillard RC; Waeber B Vasc Health Risk Manag; 2008; 4(6):1449-58. PubMed ID: 19337558 [TBL] [Abstract][Full Text] [Related]
24. The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Johansen O; Seljeflot I; Høstmark AT; Arnesen H Arterioscler Thromb Vasc Biol; 1999 Jul; 19(7):1681-6. PubMed ID: 10397685 [TBL] [Abstract][Full Text] [Related]
25. Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Boos CJ; Blann AD; Lip GY Methods Mol Med; 2007; 139():211-24. PubMed ID: 18287674 [TBL] [Abstract][Full Text] [Related]
33. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Leurs PB; Stolk RP; Hamulyak K; Van Oerle R; Grobbee DE; Wolffenbuttel BH Diabetes Care; 2002 Aug; 25(8):1340-5. PubMed ID: 12145232 [TBL] [Abstract][Full Text] [Related]
34. Circulating endothelial markers and ischemic status in peripheral occlusive arterial disease. Seigneur M; Boisseau M; Conri C; Lestage B; Amiral J; Constans J Nouv Rev Fr Hematol (1978); 1995; 37(2):171-3. PubMed ID: 7644357 [TBL] [Abstract][Full Text] [Related]
35. Thrombomodulin, von Willebrand factor and E-selectin as plasma markers of endothelial damage/dysfunction and activation in pregnancy induced hypertension. Nadar SK; Al Yemeni E; Blann AD; Lip GY Thromb Res; 2004; 113(2):123-8. PubMed ID: 15115667 [TBL] [Abstract][Full Text] [Related]
36. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Teerlink T; Gram J; Winther K; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA Eur J Endocrinol; 2008 May; 158(5):631-41. PubMed ID: 18426821 [TBL] [Abstract][Full Text] [Related]
37. Biochemical markers of endothelial activation in primary hyperparathyroidism. Fallo F; Cella G; Casonato A; Ermani M; Vettor R; Zanella S; Lumachi F Horm Metab Res; 2006 Feb; 38(2):125-9. PubMed ID: 16523414 [TBL] [Abstract][Full Text] [Related]
38. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction. Jezovnik MK; Poredos P Int Angiol; 2010 Jun; 29(3):226-31. PubMed ID: 20502419 [TBL] [Abstract][Full Text] [Related]
39. 5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes. Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T Blood Coagul Fibrinolysis; 2005 Sep; 16(6):423-8. PubMed ID: 16093733 [TBL] [Abstract][Full Text] [Related]